Bourassa, M. G. et al. Angiotensin II inhibition and prevention of atrial fibrillation and stroke. J. Am. Coll. Cardiol., 45:720–721, 2005.
Burnier, M. Angiotensin II type 1 receptor blockers. Circulation, 103:904–91, 2001.
CHARM: Granger, C.B., McMurray, J.J.V., Yusuf, S. et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin converting enzyme inhibitors; the CHARM-alternative trial. Lancet, 362:772–76, 2003.
EUROPA: The European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomized double-blind placebo-controlled multicenter trial. Lancet, 362:782–88, 2003.
Heagerty, A. M. et al. Influence of changes of blood pressure on vascular angiotensin II receptor subtype expression. Circulation, 111:956–57, 2005.
HOPE Investigators. Yusuf, S, Sleight, P, Progue, J. et al. The Heart Outcomes Prevention Evaluation Investigators: Effects of angiotensin converting enzyme inhibitor, ramipril, on death from cardiovascular

Страницы: 1 | 2